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Abstract. Autosomal recessive polycystic kidney disease (ARPKD) is a severe, typically early onset form of renal cystic
disease. The care of ARPKD patients has traditionally been the purview of pediatric nephrologists for management of systemic
hypertension and progressive renal insufficiency. However, the disease has multisystem manifestations and a comprehensive
care strategy frequently requires a multidisciplinary team. In severely affected infants, the diagnosis often is first suspected by
obstetricians when enlarged, echogenic kidneys and oligohydramnios are detected on prenatal ultrasounds. Neonatologists are
central to the care of these infants, who may have respiratory compromise due to pulmonary hypoplasia and massively enlarged
kidneys. Among neonatal survivors, a subset of ARPKD patients has clinically significant congenital hepatic fibrosis, which can
lead to portal hypertension, requiring close monitoring by pediatric hepatologists. Surgical consultation may be sought to access
pre-emptive nephrectomy to relieve mass effect, placement of dialysis access, surgical shunting procedures, and kidney and/or
liver transplantation. Recent data suggest that children with ARPKD may be at risk of neurocognitive dysfunction, and may
require neuropsychological referral. In addition to these morbidities, families of patients with ARPKD face decisions regarding
genetic testing of affected children, testing of asymptomatic siblings, or consideration of preimplantation genetic diagnosis for
future pregnancies. These issues require the input of genetic counselors, geneticists, and reproductive endocrinologists. As a
result, the management of ARPKD requires the involvement of multiple subspecialists, as well as the general pediatrician, in
a complex care network. In this review, we discuss the genetics of this disorder and provide an overview of the associated
pathobiology; outline the spectrum of clinical manifestations of ARPKD and the management of organ-specific complications;
discuss other disorders that involve genes encoding cilia-associated proteins that can clinically mimic ARPKD; review the animal
models available for preclinical studies; and finally, consider future directions for potential targeted therapies.
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1. Introduction
Autosomal recessive polycystic kidney disease
(ARPKD) (MIM 263200) is an important inherited
cause of chronic kidney disease, with an estimated
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incidence of 1 in 20,000 live births [1]. Mutations
in a single gene, PKHD1, account for essentially all
cases of ARPKD [2, 3]. The largest protein product of
PKHD1, termed the FPC/polyductin complex (FPC), is
a single-membrane spanning protein that is localized to
the apical membrane, the primary apical cilium/basal
body and the mitotic spindle [4].
Typically, ARPKD presents as an early onset dis-
order with a perinatal mortality rate of approximately
30–40% [5]. The majority of patients are identified
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either in utero or at birth with enlarged echogenic kid-
neys and oligohydramnios. At birth, the most severely
affected neonates have a critical degree of pulmonary
hypoplasia that is incompatible with survival. Renal
function, though frequently compromised, is rarely a
cause of neonatal death. In patients who survive the first
month of life, 1-yr survival rates of 92–95% have been
reported [6, 7]. Neonatal survivors have a spectrum of
clinical manifestations that primarily involve the kid-
neys and biliary tract and depend in part on the age at
presentation [6]. The basic structural defects observed
in ARPKD suggest that the terminal differentiation of
the renal collecting duct and intrahepatic biliary ducts
is disordered (Fig. 1).
The major morbidities in neonatal survivors include
severe systemic hypertension, renal impairment, and
portal hypertension [6, 8, 9]. Hyponatremia occurs in
a subset of neonates, presumably due to defects in
free water excretion [6]. Systemic hypertension usually
develops within the first 6 mo of life, often associated
with a transient improvement in glomerular filtration
rate (GFR) due to renal maturation. Subsequently, there
is a progressive, but variable decline in renal function
[10].
A subset of patients with late-onset ARPKD has a
liver-predominant phenotype with few or no manifesta-
tions of kidney disease [9]. These patients present with
portal hypertension, hepatosplenomegaly, esophageal
or gastric varices, as well as hypersplenism with
associated thrombocytopenia, anemia, and leukopenia.
Hepatocellular function is usually preserved. Ascend-
ing suppurative cholangitis is a serious complication
and can cause fulminant hepatic failure [11, 12].
Other associated features include an increased inci-
dence of culture-confirmed urinary tract infections [6],
(very rare) intracranial aneurysms [13], and growth
retardation [6], although the mechanism for the latter
is not defined. Recent data suggest that children with
Fig. 1. Classic autosomal recessive polycystic kidney disease histopathology. The histopathology in autosomal recessive polycystic kidney
disease primarily involves the kidney and liver. As schematically represented in panel A, the classic renal cystic lesion involves fusiform
dilatation of the cortical and medullary collecting ducts. Therefore, the predominant histopathological finding is dilated collecting ducts arrayed
perpendicular to the renal capsule. (B) The hepatobiliary lesion results from an architectural defect in the developing biliary tree. The normal
ramifications of the portal venous system and the lattice-like network of associated biliary ducts (left side of panel C) are disrupted due to the
ductal plate malformation (right side of panel C), likely due to a defect in terminal differentiation. The ductal plate malformation results in the
histopathological lesion, congenital hepatic fibrosis (D). Panel A is derived from reference [73] and panel C used with permission of V.E. Torres
(personal communication).
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ARPKD may be at risk of neurocognitive dysfunction,
but the specific defects and the underlying mechanisms
have yet to be characterized [14].
In addition to child-centered morbidities, the fami-
lies of ARPKD children are burdened with a number
of challenges. With advances in genetic testing and
imaging methodologies, families face decisions about
genetic testing of a symptomatic child, as well as
genetic testing and/or imaging evaluation of asymp-
tomatic children. For future pregnancies, there are
issues of prenatal diagnosis and consideration of new
reproductive technologies such as pre-implantation
genetic diagnosis (PGD). Disease progression prompts
decisions about dialysis modalities and/or transplanta-
tion, e.g. kidney, liver, or sometimes both. Therefore,
the multidisciplinary care team must be well-versed
in the genetics of ARPKD, the pathobiology of the
disease, clinical management strategies, and the psy-
chosocial implications for affected families.
2. ARPKD genetics
All typical forms of ARPKD are caused by muta-
tions in PKHD1, a large, ∼500 kb gene [2, 3]. The
longest open reading frame comprises 67 exons that
encodes FPC. There is evidence for extensive alter-
native splicing of this gene [15]. Whether all the
predicted alternative PKHD1 transcripts are translated
into proteins and what their biological functions may
be remains unknown. In general, it appears that a criti-
cal amount of full-length protein is required for normal
biological functions (e.g. tubular differentiation and
maintenance of tubular architecture).
2.1. Human mutations
ARPKD mutations have been identified along the
entire length of the PKHD1 gene, and multiple muta-
tion types have been characterized as pathogenic. To
date, almost 750 pathogenic mutations have been cata-
logued in the ARPKD mutation database [16], of which
approximately half are missense changes. The most
common mutation is a missense mutation in exon 3,
c.107 C>T (p.Thr36Met), which accounts for approx-
imately 20% of all mutant alleles [8]. This mutation
has been observed in a large number of unrelated
patients, but typically in the context compound het-
erozygosity, with a second distinct mutant allele [17].
In general, PKHD1 does not appear to harbor muta-
tional hotspots and a large proportion of mutations are
unique to a single pedigree [17, 18]. The first PKHD1
founder mutation has recently been described in a
cohort of Afrikaner ARPKD patients, involving a mis-
sense change in exon 20, i.e. c.1880T>A (p.M627K)
substitution [19].
2.2. Genotype-phenotype correlations
Given the diversity of PKHD1 mutations, most
patients are compound heterozygotes, that is they carry
two different mutant alleles. The functional effect of
any particular mutant allele can be difficult to char-
acterize. Nevertheless, several themes have emerged
from genotype-phenotype studies. First, in a study of
fetuses and neonates with ARPKD, Denamur et al. [20]
determined that when adjusted for gestational age, the
extent of collecting duct dilatation, but not portal fibro-
sis, was significantly correlated with the presence of
two truncating mutations (severe genotype). Of note,
in this study, the presence of at least one missense muta-
tion did not guarantee survival to the neonatal period. In
general, patients with two truncating mutations often,
but not invariably, have a severe phenotype leading
to perinatal demise [18]. However, there are notable
exceptions, e.g. a child homozygous for a largePKHD1
deletion who survived well past the neonatal period
[21]. While most missense mutations are associated
with milder disease, a number of missense mutations
result in severe phenotypes when combined with a
truncating mutation or occurring in the homozygous
state [18].
In addition, significant phenotypic variability in a
subset of affected siblings suggests that genetic modi-
fiers modulate disease expression. For example, in one
study of 126 unrelated families with more than one
affected child, 20 sibships demonstrated widely dis-
cordant phenotypes (perinatal lethality in one sibling
and survival into childhood in the other) [7].
3. ARPKD pathobiology
The largest protein product of PKHD1, termed FPC,
is a single-membrane spanning protein with a long
extracellular N-terminus and short cytoplasmic tail
[22]. A subset of membrane-bound FPC appears to
undergo notch-like proteolytic processing, with shed-
ding of the extracellular domain into the tubular lumen
and nuclear translocation of the C-terminus, where it
may play a role in transcriptional regulation [23].
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During fetal development, PKHD1 is expressed
widely and is found in the neural tube, bronchi, pri-
mordial gut, early ureteric bud, mesonephric tubules,
adrenal cortex, and immature hepatocytes, suggesting
a role in organ development and tubular morphogen-
esis. In adult tissues, FPC is expressed predominantly
in the kidney (primarily in collecting ducts and thick
ascending loops of Henle) and the ductal epithelia of
the liver and the pancreas [2, 22, 24–26]. In renal tubu-
lar and biliary epithelial cells, FPC localizes to apical
membranes, the primary cilia/basal body, and mitotic
spindle [4].
The specific functions of FPC have yet to be
fully characterized. However, numerous other pro-
teins associated with other hepato-renal fibrocystic
diseases (e.g. autosomal dominant polycystic kidney
disease [ADPKD], nephronophthisis, Meckel-Gruber,
Joubert, Bardet-Biedl and other ciliary chondrodys-
plasias syndromes) (Table 1) also localize to the
primary cilia/basal body (Fig. 2) [27].
This suggests a central role for the primary cilium
in the development and maintenance of renal tubu-
lar architecture, perhaps via mechanisms such as flow
sensing and establishment of planar cell polarity. The
ADPKD proteins, polycystin-1 and polycystin-2, inter-
act physically and appear to function via a common
signaling pathway [28]; in turn, FPC has been shown
to interact with polycystin-2 and appears to regulate
its expression and function [29]. In animal studies,
mice harboring mutations in both Pkhd1 and either
of the ADPKD genes (Pkd1 or Pkd2) display cystic
phenotypes much more severe those seen with either
mutation alone, suggesting genetic interaction in vivo
[29].
4. Clinical diagnosis
4.1. Imaging
ARPKD is typically first detected on routine pre-
natal ultrasound, with the findings of symmetrically
enlarged, echogenic kidneys (due to multiple micro-
scopic cysts) and medullary hyperechogenicity due to
loss of corticomedullary differentiation [30]. Discrete
cysts can be observed, but are not common [31]. Oligo-
hydramnios may be present due to poor fetal urine
output [6, 30]. However, normal sonographic findings
do not necessarily exclude the diagnosis of ARPKD in
an at risk fetus, since abnormalities may not be seen
until late in the second trimester (or beyond), even in
fetuses who present with a severe phenotype at birth [6,
30, 32]. In addition, the presence or absence of oligo-
hydramnios does not always correlate with disease
severity or degree of pulmonary insufficiency [32].
Table 1
ARPKD and hepatorenal fibrocystic disease phenocopies
Disease Gene(s) Renal disease Hepatic disease Systemic features Prevalence
ARPKD PKHD1 Collecting duct
dilatation
CHF; Caroli syndrome no ∼1 in 20,000
ADPKD PKD1; PKD2 Cysts along entire
nephron
Biliary cysts; CHF (rare) yes - adults ∼1 in 1,000
Nephronophthisis NPHP1-18 Cysts at the
cortico-medullary
junction
CHF some ∼1 in 100,000
Joubert syndrome and
related disorders
JBTS1-22 Cystic dysplasia;
NPHP
CHF; Caroli syndrome yes ∼1 in 100,000
Bardet-Biedel
syndrome
BBS1-19 Cystic dysplasia;
NPHP
CHF yes ∼1 in 140,000
Meckel-Gruber
syndrome
MKS1-11 Cystic dysplasia CHF yes ∼1 in 250,000
Oral-facial-digital
syndrome type I
OFD1 Glomerular cysts CHF (rare) yes rare
Glomerulocystic
disease
PKD1; HNF1B;
UMOD
Enlarged; normal or
hypoplastic kidneys
CHF (with PKD1 mutations) some rare
Short-Rib Thoracic
Dysplasia
SRTD1-12 Cystic dysplasia;
NPHP
CHF; Caroli syndrome yes rare
Renal-hepatic-
pancreatic dysplasia
(Ivemark II)
NPHP3, NEK8 Cystic dysplasia Intrahepatic biliary
dysgenesis
yes rare
Zellweger syndrome PEX1-3;5-7;10-
14;16;19;26
Renal cortical
microcysts
Intrahepatic biliary
dysgenesis
yes rare
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Fig. 2. The primary cilium with associated cystoproteins, and autosomal recessive polycystic kidney disease related pathways. The cilium
concentrates and organizes a number of channels, receptors, and effectors, e.g. transcription factors and proteolytic fragments of cystoproteins
(panel A). Almost all cystoproteins, including polycystins 1 and 2, FPC, the nephrocystins, the BBS proteins, OFD1, and TSC1 (or hamartin),
all localize to the cilia/centrosome complex, providing compelling evidence that this complex is critical in the pathogenesis of renal cystic
disease. Cilia appear to play a role in maintaining the balance between cell proliferation and differentiation through sensing the extracellular
milieu, responding to mechanical cues, and modulating different signaling cascades. Ciliary dysfunction contributes to increased intracellular
accumulation of cAMP and activation of mTOR, features common to cystic epithelia in human and rodent models of renal cystic disease (panel
A). In addition, dysregulation of the epidermal growth factor receptor (EGFR) axis is a common feature of cystic epithelia (panel B). Each of these
abnormal signaling pathways represents potential targets for therapeutic intervention. FPC = Fibrocystin-polyductin complex; BBS = Bardet-
Biedl syndrome; cAMP = Cyclic adenosine monophosphate; mTORC1 = Mammalian target of rapamycin complex 1; OFD1 = Oral-facial-digital
syndrome, type 1; TSC1 = Tuberous sclerosis type 1; V2 R=Vasopressin 2 receptor; RTKi = Receptor tyrosine kinase inhibitor; Srci = Src kinase
inhibitor.
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As discussed below, ARPKD belongs to a group
of disorders described as hepato-renal fibrocystic dis-
eases [33] (Table 1). While most of these disorders
are characterized by large, echogenic kidneys in the
fetus and neonate, they can sometimes be distinguished
by ultrasonography [31]. With respect to the poly-
cystic kidney diseases, ARPKD kidneys in utero are
typically hyperechogenic and display decreased corti-
comedullary differentiation due to the hyperechogenic
medulla. With high-resolution ultrasound, the radial
array of dilated collecting ducts can be observed. In
comparison, ADPKD kidneys in utero tend to be mod-
erately enlarged with a hyperechogenic cortex and
relatively hypoechogenic medulla causing increased
corticomedullary differentiation [34].
Kidney size in children with ARPKD typically peaks
at 1 to 2 yrs of age, then gradually declines relative to
the child’s body size, and stabilizes by 4 to 5 yrs [4]. As
patients age, there is increased medullary echogenic-
ity with scattered small cysts, measuring less than
2 cm in diameter. These cysts and progressive fibrosis
can alter the usual kidney contour, causing ARPKD
in some older children to be mistaken for ADPKD
[35]. Contrast-enhanced computed tomography scan-
ning can be useful in delineating the renal architecture
in these children. Bilateral pelvicaliectasis and renal
calcifications have been reported in 25% and 50% of
ARPKD patients respectively [9, 36]. In adults with
medullary ectasia alone, the cystic lesion may be con-
fused with medullary sponge kidney.
The liver may be either normal in size or enlarged. It
is usually less echogenic than the kidneys. Prominent
intrahepatic bile duct dilatation suggests associated
Caroli syndrome. With age, the portal fibrosis tends
to progress and in older children, ultrasound typically
shows hepatosplenomegaly and a patchy increase in
hepatic echogenicity [37, 38].
4.2. Genetic testing in ARPKD
Mapping of the ARPKD locus in the mid-1990s led
to haplotype (linkage-based) analysis for genetic diag-
nosis, provided DNA from a previously affected child
and the parents was available.
In the last decade, the identification of the PKHD1
gene has allowed genetic diagnosis by direct (Sanger
method-based) DNA sequencing. Initially, a wide
range of mutation detection rates were reported. More
recent studies indicate that bi-allelic mutations are
detected in 80–87% of tested alleles, and about 95% of
ARPKD patients are found to have at least one PKHD1
mutation. However, as discussed above, sequenc-
ing results have limited prognostic value. While the
presence of two truncating mutations is generally
incompatible with survival, clinical consequences of
other mutation types can be difficult to predict. Of
note, an estimated 44% of PKHD1 mutations involve
missense changes [16].
Clinical genetic testing laboratories (listed at
GeneTests, www.genetests.org) offer direct sequenc-
ing of the entire coding region, with mutation detection
rates of approximately 80%. Direct sequencing cannot
detect all mutations, for example, those in non-coding
exons, or in promoter or regulatory regions. Some lab-
oratories also offer multiplex ligation-dependent probe
amplification to detect large deletions or genomic
rearrangements, although the frequency of such large
genomic alterations appears to be quite low [21]. In
families with more than one affected child, haplotype
analysis remains a valuable tool when only one or no
PKHD1 mutations have been identified [39].
As discussed below, several other disorders mimic
the clinical presentation of ARPKD, further com-
pounding the molecular diagnosis of ARPKD. For
example, patients with mutations in the ADPKD
genes, PKD1 and PKD2, can present with early onset
renal cystic disease indistinguishable from ARPKD.
In addition, a number of other hepato-renal fibrocys-
tic diseases (Table 1) have clinical manifestations that
overlap with ARPKD.
Thus, mutational analysis of PKHD1 using cur-
rent single-gene testing methodologies should not be
considered a first-line diagnostic strategy for infants
and children presenting with an ARPKD-like phe-
notype. It is expensive and potentially confounded
by the existence of phenocopy disorders. Moreover,
the high frequency of missense mutations makes
pathogenicity predictions challenging, and particu-
lar caution is required when novel or rare missense
changes are detected. The one clear exception to
this guidance is in the context of planned PGD
where putative PKHD1 mutations transmitted from the
mother and father, respectively, must be prospectively
identified.
This testing conundrum may soon be resolved with
advances in next-generation DNA sequencing, where
massively-parallel sequencing technologies can simul-
taneously evaluate dozens of genes of interest in
a single test. This diagnostic approach promises to
be particularly powerful for patients with clinically
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unclassified cystic kidneys in whom the differential
diagnosis can be broad [40].
4.3. PGD
In families who have had a previous child with severe
ARPKD, PGD offers an alternative to prenatal diagno-
sis for a subsequent pregnancy. The procedure requires
prospective identification of the PKHD1 mutations
transmitted from each parent. The couple then must
undergo in vitro fertilization. The resulting embryo is
biopsied at the 8-cell stage, with removal of 1–2 embry-
onic cells for genetic testing [41]. There are at least two
reported cases of PGD guiding the birth of unaffected
infants in at risk families [42, 43].
5. Management and prognosis
5.1. Fetal monitoring
Once a presumptive diagnosis of ARPKD is made,
ultrasonography should be performed every 2 to 3 wks
for serial assessment of the renal size and amniotic fluid
volume. The gestational age at onset of oligohydram-
nios is variable in ARPKD. Onset of oligohydramnios
in the second trimester may be, but is not invariably,
associated with pulmonary hypoplasia [44]. A study
of 46 fetuses with severe genitourinary anomalies [45]
demonstrated that after 26 wk gestational age, a total
lung volume value of <0.90 by magnetic resonance
imaging has a sensitivity of 77.8% and specificity of
95% for predicting non-survival.
5.2. Neonatal issues
The estimated rate of neonatal mortality in ARPKD
patients is approximately 30–40%, primarily due to
respiratory compromise. One-year survival rates of 92-
–95% have been reported in patients who survive the
first month of life [6, 7]. Neonatal pulmonary hypopla-
sia, often complicated by pneumothoraces, is a major
cause of neonatal mortality [46]. Aggressive inter-
ventions such as unilateral or bilateral nephrectomies
and continuous hemofiltration have been advocated
for neonatal respiratory management. However, these
interventions are based on limited set of small case
reports and case series. Evidence-based guidelines
for clinical practice will require prospective, well-
controlled studies.
5.3. Post-neonatal management
5.3.1. Systemic hypertension
For those children who survive the perinatal period,
systemic hypertension is a major issue, with a preva-
lence of 55–75% and onset that typically precedes
the decline in GFR. The pathogenic mechanism(s)
remain elusive and the data, particularly regarding
the role of renin-angiotensin-aldosterone system acti-
vation, is controversial. Interestingly, a recent study
in the polycystic kidney (PCK) rat model reported
a significant increase in intrarenal, but not systemic,
renin-angiotensin-aldosterone system activation [47].
This finding may explain why previous human studies
had not detected increased plasma renin levels.
Angiotensin converting enzyme inhibitors and
angiotensin receptor blockers are widely used as ther-
apeutic agents. However, combination angiotensin
converting enzyme inhibitors and angiotensin recep-
tor blockers therapy is not recommended, due to
increased risk of side effects. Multi-agent therapy
may be required and therapeutic strategies should be
directed towards optimizing blood pressure control,
while minimizing further reduction in GFR in the
context of chronic kidney disease (CKD) [48]. The
management of ARPKD children with declining GFR
should follow the standard guidelines established for
chronic CKD in pediatric patients [49].
5.3.2. Other renal issues
Hyponatremia occurs in up to 25% of neonates and
may be due to an inability to maximally dilute the urine
[6]. Children with ARPKD appear to be at higher risk
for urinary tract infections, possibly due to urinary sta-
sis within the cystic, dilated collecting ducts. Urinary
tract infections have been reported at rates of around
20-–50% in various cohorts, and are more common in
females. Renal calcifications have also been reported
to be common in older children with ARPKD, and
may be related to hypocitraturia and a defect in urine
acidification due to CKD [50]. Given their relative uri-
nary concentrating defect, ARPKD children should be
monitored for dehydration during intercurrent illnesses
associated with fever, tachypnea, nausea, vomiting or
diarrhea.
5.3.3. Chronic renal insufficiency
Most ARPKD patients progress to end-stage renal
disease (ESRD), but the age at onset is highly variable
and depends in part on the age at initial presentation,
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e.g. 25% of patients diagnosed in the perinatal
period require renal replacement therapy by 11 yrs,
whereas only 25% of those who presented after 1
mo of age require renal replacement therapy by age
32 yr [10].
5.3.4. Hepatobiliary manifestations
ARPKD is invariably associated with congenital
hepatic fibrosis, the result of a developmental defect
in ductal plate development (Figs. 1C and D). In a
subset of patients, the associated progressive portal
tract fibrosis causes portal hypertension and associ-
ated complications of hypersplenism and varices [37].
Platelet counts, prothrombin time, splenic volume, and
Doppler flow studies have been correlated with the
severity of portal hypertension and should be serially
monitored [38]. Liver transaminases are generally nor-
mal, with abnormalities in serum alkaline phosphatase
and -glutamyltransferase evident in only a fraction of
patients. Medical management includes sclerotherapy
or variceal banding; whereas surgical approaches such
as portocaval or splenorenal shunting may be indicated
in some patients [37]. Ascending cholangitis is another
important complication, and is a leading cause of mor-
bidity and mortality in ARPKD patients, particularly
after renal transplantation [51]. Meticulous evalua-
tion is required for suspected bacterial cholangitis and
if indicated, aggressive antibiotic therapy should be
initiated.
5.3.5. Transplantation
Since ARPKD is a recessive disorder, either parent
may be a suitable kidney donor. However, sub-
tle renal and liver sonographic abnormalities have
recently been described in ARPKD parents [52], war-
ranting particular caution in the donor evaluation.
Native nephrectomies may be indicated in patients
with massively enlarged kidneys to allow allograft
placement.
In one survey, about 7% of long-term survivors were
reported to require liver transplantation, with primary
indications being significant portal hypertension or
recurrent cholangitis [6]. In some patients, combined
kidney-liver transplantation may be appropriate [53].
Indications include the combination of renal failure
and either recurrent cholangitis or significant compli-
cations of portal hypertension, e.g. recurrent variceal
bleeding, refractory ascites, and the hepatopulmonary
syndrome [37].
5.3.6. Prognosis
The relationship between renal and hepatic dis-
ease severity in ARPKD is unclear, with most studies
demonstrating no significant correlation. A subset of
patients with late-onset ARPKD can express a liver-
predominant phenotype with few or no manifestations
of kidney disease [9].
Effective management of neonatal morbidities, and
systemic and portal hypertension, coupled with suc-
cessful renal replacement therapy and transplantation
options, has allowed for long-term patient survival.
Therefore, the prognosis in ARPKD, particularly for
those children who survive the first month of life, is
far less bleak than previously thought and aggressive
medical therapy is warranted.
5.4. Genetic counseling
Most ARPKD patients are compound heterozygotes
and the functional effect of any particular mutant allele
can be difficult to define. In general, patients with two
truncating mutations have a severe phenotype, leading
to perinatal demise [18]. However, there are notable
exceptions, e.g. a child homozygous for a largePKHD1
deletion who survived well past the neonatal period
[21]. While most missense mutations are associated
with milder disease, a number of missense mutations
result in severe phenotypes when combined with a
truncating mutation or occurring in the homozygous
state [18]. In addition, significant phenotypic variabil-
ity between and within families suggests that genetic
modifiers modulate disease expression. These data can
complicate genetic counseling and caution must be
exercised in predicting the clinical outcome of future
affected children [54].
6. Disorders mimicking ARPKD (non-PKHD1
genes)
Studies over the past decade have demonstrated that
an increasing number of single gene disorders that
involve renal cystic disease and extra-renal phenotypes
disrupt proteins involved in the structure/function of
the primary cilium, a sensory organelle of the cell
that extends from the apical plasma membrane. As
a result, this very broad class of disorders is increas-
ingly referred to the “ciliopathies” [55–57]. These data
provide collective evidence that ciliary dysfunction is
potentially a central mechanism in renal cystogenesis
[22, 58, 59].
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A subset of the ciliopathies is characterized by fibro-
cystic disease of the kidney and dysgenesis of the
porto-biliary tract (congenital hepatic fibrosis and/or
Caroli syndrome), prompting a redefinition of these
disorders as hepato-renal fibrocystic diseases [33, 60].
While ARPKD is considered as the flagship disorder
in this new phenotypic sub-classification, defects in
the other hepato-renal fibrocystic diseases genes may
mimic (phenocopy) ARPKD (Table 1). For example,
2% of all ADPKD patients express an early onset,
severe phenotype that is clinically indistinguishable
from ARPKD [61]. Rarer recessive disorders such
as nephronophthisis, Joubert syndrome, Bardet-Biedl
syndrome, Meckel-Gruber syndrome, and various cil-
iary chondrodysplasias also have variable degrees of
renal and/or biliary involvement (Table 1). Finally, the
renal phenotype of ARPKD can also be mimicked
by mutations in the HNF1B gene, which encodes the
transcription factor, hepatocyte nuclear factor-1 beta
(HNF1B).
7. Animal models
At least eight mouse Pkhd1 models have been
described to date. The majority were generated by
gene-targeting methods, while one model arose spon-
taneously as a truncating mutation in exon 48 (Table 2).
In addition, the rat PCK model developed sponta-
neously in the Crj:CD/SD strain [62], due to an exon
skipping event involving Pkhd1 exon 36, leading to a
frame shift mutation [2].
Of note, while an ARPKD-like liver phenotype
is invariably present in all murine Pkhd1 models, a
renal phenotype is either absent or very mild in its
expression, typically involving the proximal tubules
and not the collecting duct. Interestingly, several mod-
els also express a severe pancreatic ductal phenotype,
whereas clinically significant pancreatic disease in
human ARPKD is quite rare.
The mechanism that underlies the limited renal
phenotype remains unclear. However, genetic back-
ground appears to have a major impact on renal
pathology, suggesting the genetic modifiers modulate
renal disease expression. For example, in the Pkhd1
del3-4 model, initial crosses of outbred heterozygotes
resulted in a high rate of prenatal and perinatal lethality
and a significant renal cystic lesion, but these phe-
notypes disappeared with subsequent inbreeding of
viable ARPKD mice [63]. In the rat PCK model,
transfer of the Pkhd1 mutation from the original
Sprague-Dawley background onto the Fawn-Hooded
hypertensive genetic background resulted in signifi-
cant attenuation of the renal cystic lesion, but had no
effect on the hepatic phenotype [64].
While orthologous Pkhd1 models in the mouse and
rat do not phenocopy human ARPKD, there are at
least two non-orthologous mouse models in which the
renal and biliary lesions closely resemble the human
ARPKD phenotype. The congenital polycystic kid-
ney (cpk) model involves a truncating mutation in the
Cys1 gene that is predicted to completely disrupt the
function of cystin, the encoded cilia-associated pro-
tein [65]. The BALB/c polycystic kidney (bpk) mouse
model results from a splicing defect involving one of
two isoforms encoded by Bicc1, thereby partially dis-
rupting the function of bicaudal C, an RNA-binding
protein [66]. While the common phenotype is sugges-
Table 2
Mouse Pkhd1 models
Type Symbol Investigator Mutation Pkhd1−/− Kidney Other
Targeted allele Pkhd1tm1Rbu R. Buettner Exon 40 skipping viable none Liver∗
Targeted allele Pkhd1tm1Cjwa C.J. Ward Exon 2 skipping viable PT dilatation Liver∗, Pancreas∗∗
Targeted allele Pkhd1tm1Ggg G.G. Germino Exon 3-4 deletion PL (29% survive) TAL and CD Liver∗, Pancreas∗∗
Targeted allele Pkhd1tm1Gwu G. Wu Exon 15-16 deletion viable PT and MCD
dilatation
Liver∗
Targeted allele Pkhd1tm1Som S. Somlo Exon 4 deletion viable none Liver∗, Pancreas∗∗
Targeted allele Pkhd1tm1Sswi S.S. Williams Exon 1-3 deletion viable PT dilatation Liver∗
Targeted allele Pkhd1tm2Cjwa C.J. Ward Transcription
termination intron 2
viable PT dilatation Liver∗
Spontaneous allele Pkhd1cyli L.M.
Guay-Woodford
Exon 48
(c.7589delGGinsT)
viable none Liver∗
Compiled from the Mouse Locus Catalogue. http://www.informatics.jax.org/allele/summary?markerId=MGI:2155808. PL = Partial perinatal
lethality. PT = Proximal tubule; TAL = Thick ascending limb; CD =Collecting duct; MCD = Medullary collecting duct; Liver∗=Intra-hepatic
biliary ductal dysgenesis; Pancreas∗∗=Intra-pancreatic ductal dysgenesis.
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tive, it remains to be determined whether cystin and
bicaudal C function in a common molecular pathway
as FPC.
8. Perspectives on targeted therapies
Activation of the cyclic adenosine monophos-
phate (cAMP)-signaling and the mammalian target of
rapamycin (mTOR) pathways, as well as dysregulation
of the epidermal growth factor receptor (EGFR) axis
have been well described in human ADPKD, ARPKD,
and experimental PKD models [4] (Fig. 2).
Agents such as tolvaptan, that antagonize the vaso-
pressin 2 receptor (V2 R) and decrease intracellular
cAMP, have been effective in attenuating cystic dis-
ease progression in the PCK rat [67] (Fig. 2A). The
potential efficacy of V2 R antagonists has been fur-
ther demonstrated by genetic studies in which PCK
rats were crossed with vasopressin knock-out rats to
generate double mutant progeny with varying levels of
circulating vasopressin. PCK rats lacking vasopressin
showed lower intra-renal cAMP activity and almost
complete inhibition of cystogenesis [68]. In addi-
tion, when treated with somatostatin analogs, which
also reduce intracellular cAMP activation, PCK rats
demonstrated reduced renal and hepatic cyst forma-
tion, with pasireotide showing greater benefit than
octreotide [69].
Agents that inhibit the EGFR axis have been shown
to significantly reduce the biliary and renal abnor-
malities in various murine models of ARPKD [70]
(Fig. 2B). Furthermore, therapies directed at down-
stream targets of both the cAMP and EGFR pathways,
such as Src, may prove efficacious, as demonstrated
by one study of Src inhibition in ARPKD mice that
led to improvement in both the biliary and renal
abnormalities [71].
On the other hand, not all signaling defects read-
ily translate into successful pre-clinical trials. For
example; a trial with mTOR inhibition in PCK rat
model failed to impact progression of kidney and liver
disease [72]. The paradox between the tissue find-
ings of mTOR activation and the lack of therapeutic
efficacy in this one pre-clinical trial remains to be
explained.
Despite the generally promising studies in experi-
mental models, specific disease-targeting therapies to
slow progression of human ARPKD remain elusive.
Effective human clinical trial designs continue to be
stymied by the lack of non-invasive predictive and
prognostic markers to track disease progression and
assess therapeutic impact on disease course. Current
efforts are focused on optimizing pre-clinical stud-
ies with targeted therapeutics in experimental models
and developing non-invasive markers for human clin-
ical trials, which assess progression endpoints and are
acceptable to regulatory agencies. Therefore, the goal
of identifying targeted treatment that slows or arrests
disease progression remains a work in progress.
9. Conclusion
In conclusion, ARPKD is a multifaceted genetic
disorder, which requires expert, multi-disciplinary
management. Investigations over the last decade have
yielded new insights about the genetics and pathobiol-
ogy of this disorder. Patient survival has been improved
by advances in supportive therapy for neonates, treat-
ment of systemic and portal hypertension, dialysis
modalities, and transplantation. However, there are
many remaining challenges to surmount in order to
fully elucidate the mechanisms of disease expression
and progression. Specifically, advances in understand-
ing the function of the FPC protein, its putative
isoforms, and the role of genetic modulators are key
to defining pathogenetic mechanisms and identify-
ing specific pathways for targeted therapeutics. In
addition, improved technologies for non-invasive dis-
ease monitoring are essential for developing more
precise predictive and prognostic markers. Newer
study design methodologies, coupled with more robust
predictive markers will set the stage for develop-
ing human clinical trials that can rigorously evaluate
the efficacy of targeted therapeutic strategies (with
single or multiple agents). The ultimate goal is to
identify disease-specific markers that predict progno-
sis and validate targeted therapies to slow or even
arrest the inexorable progression of ARPKD-related
morbidities.
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